2015
Novel RAAS agonists and antagonists: clinical applications and controversies
Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nature Reviews Endocrinology 2015, 11: 242-252. PMID: 25666495, PMCID: PMC7097622, DOI: 10.1038/nrendo.2015.6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAngiotensin receptor blockersRelative risk reductionBlood pressure homeostasisRAAS peptidesAldosterone systemReceptor blockersCardiorenal diseaseVascular injuryPressure homeostasisReceptor densityTarget organsAutocrine systemEnzyme inhibitorsVascular structuresClinical applicationRisk reductionVariety of sitesHaemodynamicsBlockersAgonistsInjuryAntagonistRAASDiseasePeptides
2009
Aliskiren and the Kidney: Beyond Hypertension
Trimarchi H, Orías M. Aliskiren and the Kidney: Beyond Hypertension. Nephrology Research & Reviews 2009, 1: 1-4. DOI: 10.4081/nr.2009.e1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPlasma renin activityRenin activityReceptor blockersGlomerular diseaseRenin angiotensin aldosterone systemAldosterone receptor blockersEndstage kidney diseaseAngiotensin aldosterone systemAngiotensin receptor blockersRenal disease progressionSecondary glomerular diseasesUse of angiotensinRenin-angiotensin systemUrinary protein excretionNew therapeutic optionsDiabetic nephropathyProtein excretionKidney diseaseTherapeutic optionsDisease progressionComplete blockadeUrinary proteinSide effectsEnzyme inhibitorsImportant cause